What Is the Impact of the Novel Coronavirus and the Vaccination on Guillain-Barre Syndrome?

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2023 Sep 20

PMID 37728848

Authors

Yinuo Chen

Kezheng Li

Wenjing Lv

Jiali Xie

Yuqin Qian

Can Cui

Binbin Deng

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has resulted in devastating medical and economic consequences worldwide over the past 3 years. As the pandemic enters a new stage, it is essential to consider the potential impact on rare diseases such as Guillain-Barre syndrome (GBS), which has been intimately associated with COVID-19 since the first COVID-19-related GBS case was reported in January 2020. There are notable differences between COVID-19-related GBS and GBS without COVID-19 in terms of diagnostic types and clinical manifestations. Furthermore, with the widespread administration of COVID-19 vaccines, there have been reports of GBS occurring shortly after vaccination, which requires close attention despite its rarity. This review also explores the vaccines associated with heightened GBS risks, offering insights that may guide vaccination policies and clinical practice. To provide a visual summary of these findings, we have included a graphical abstract.

References

Willison H, Jacobs B, van Doorn P . Guillain-Barré syndrome. Lancet. 2016; 388(10045):717-27. DOI: 10.1016/S0140-6736(16)00339-1. View

Lapostolle F, Schneider E, Vianu I, Dollet G, Roche B, Berdah J . Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. Intern Emerg Med. 2020; 15(5):813-817. PMC: 7260461. DOI: 10.1007/s11739-020-02379-z. View

Romero-Sanchez C, Diaz-Maroto I, Fernandez-Diaz E, Sanchez-Larsen A, Layos-Romero A, Garcia-Garcia J . Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020; 95(8):e1060-e1070. PMC: 7668545. DOI: 10.1212/WNL.0000000000009937. View

Lechien J, Chiesa-Estomba C, Place S, Van Laethem Y, Cabaraux P, Mat Q . Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020; 288(3):335-344. PMC: 7267446. DOI: 10.1111/joim.13089. View

Khedr E, Abo-Elfetoh N, Deaf E, Hassan H, Amin M, Soliman R . Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals. Neuroepidemiology. 2021; 55(2):109-118. PMC: 8018217. DOI: 10.1159/000513647. View

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q . Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6):683-690. PMC: 7149362. DOI: 10.1001/jamaneurol.2020.1127. View

Filosto M, Piccinelli S, Gazzina S, Foresti C, Frigeni B, Servalli M . Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2020; 92(7):751-756. DOI: 10.1136/jnnp-2020-324837. View

He Y, Brouwers B, Liu H, Liu H, Lawler K, Mendes de Oliveira E . Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior. Nat Med. 2022; 28(12):2537-2546. PMC: 9800280. DOI: 10.1038/s41591-022-02106-5. View

Kevadiya B, Machhi J, Herskovitz J, Oleynikov M, Blomberg W, Bajwa N . Diagnostics for SARS-CoV-2 infections. Nat Mater. 2021; 20(5):593-605. PMC: 8264308. DOI: 10.1038/s41563-020-00906-z. View

10.

Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi S, Razvi S . Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021; 27(12):2144-2153. PMC: 8629105. DOI: 10.1038/s41591-021-01556-7. View

11.

Ray S, Abdel-Mannan O, Sa M, Fuller C, Wood G, Pysden K . Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health. 2021; 5(9):631-641. PMC: 8279959. DOI: 10.1016/S2352-4642(21)00193-0. View

12.

LaRovere K, Riggs B, Poussaint T, Young C, Newhams M, Maamari M . Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol. 2021; 78(5):536-547. PMC: 7936352. DOI: 10.1001/jamaneurol.2021.0504. View

13.

Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y . The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021; 20(4):102792. PMC: 7892316. DOI: 10.1016/j.autrev.2021.102792. View

14.

Khan F, Sharma P, Pandey S, Sharma D, V V, Kumar N . COVID-19-associated Guillain-Barre syndrome: Postinfectious alone or neuroinvasive too?. J Med Virol. 2021; 93(10):6045-6049. PMC: 8426929. DOI: 10.1002/jmv.27159. View

15.

Zhao H, Shen D, Zhou H, Liu J, Chen S . Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?. Lancet Neurol. 2020; 19(5):383-384. PMC: 7176927. DOI: 10.1016/S1474-4422(20)30109-5. View

16.

Finsterer J, Scorza F . Guillain-Barre syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatr Neurosurg. 2021; 57(1):55. PMC: 8094972. DOI: 10.1186/s41983-021-00310-7. View

17.

Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M . Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2020; 268(4):1133-1170. PMC: 7445716. DOI: 10.1007/s00415-020-10124-x. View

18.

Uncini A, Vallat J, Jacobs B . Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. 2020; 91(10):1105-1110. DOI: 10.1136/jnnp-2020-324491. View

19.

Carrillo-Larco R, Altez-Fernandez C, Ravaglia S, Vizcarra J . COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. Wellcome Open Res. 2020; 5:107. PMC: 7509591. DOI: 10.12688/wellcomeopenres.15987.2. View

20.

Manganotti P, Bellavita G, DAcunto L, Tommasini V, Fabris M, Sartori A . Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: A case series. J Med Virol. 2020; 93(2):766-774. PMC: 7405169. DOI: 10.1002/jmv.26289. View